Related Experiment Videos

Obstetric outcomes in women with elevated maternal serum human chorionic gonadotropin

Dena Towner¹, Sonal Gandhi, Dina El Kady

¹Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of California at Davis, Sacramento, CA, USA.

American Journal of Obstetrics and Gynecology

|April 29, 2006

Abstract

Objective:

This study was undertaken to assess outcomes in unselected women with maternal serum human chorionic gonadotropin (MShCG) 2.0 MoM or greater.

Study Design:

This is an observational cohort study of 309 women with MShCG 2 MoM or greater and 309 women of the same age and ethnicity with MShCG less than 2.0 MoM who were evaluated for preterm delivery (PTD), preeclampsia, stillbirth, birth weight 10% or less, and birth weight 90% or greater (larger for gestational age [LGA]). Confounding variables evaluated were nulliparity, prior PTD, chronic hypertension, diabetes, and maternal serum alpha-fetoprotein and estriol.

Results:

There was no overall increase in adverse outcomes despite associations found with PTD for preeclampsia with MShCG 3.0 MoM or greater (odds ratio [OR] 5.9, CI 1.5-23.2) and PTD for fetal indications with MShCG 4.0 MoM or greater (OR 45.5, CI 4.1-509). There was an increase of LGA infants with MShCG 3.0-3.9 MoM (OR 2.5, CI 1.0-5.8).

Conclusion:

Adverse pregnancy outcome is associated with MShCG 3.0 MoM or greater, thus increased surveillance is not warranted with lower values.

Related Concept Videos

Oogenesis

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...

Ovarian Cycle

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...

Articles linked to this work by shared authors, journal, and citation graph.

Recurrent Pubic Osteomyelitis and Urosymphyseal Fistula in a Prostate Cancer Survivor: A Multidisciplinary Management Challenge.

Journal of community hospital internal medicine perspectives·2026

Early tumour size changes from neoadjuvant chemotherapy as a predictor of pathologic response in breast cancer.

PloS one·2026

Provider level facilitators and barriers towards neoadjuvant chemotherapy for triple negative and HER2 + breast cancer: a survey of Ontario surgeons.

Breast cancer research and treatment·2026

Quantitative Ultrasound Texture Analysis of Breast Tumor Responses to Chemotherapy: Comparison of a Cart-Based and a Wireless Ultrasound Scanner.

Journal of imaging·2026

Quantitative ultrasound imaging for predicting response and guiding personalized neoadjuvant chemotherapy in breast cancer: randomized phase 2 clinical trial results.

NPJ precision oncology·2025

Validation of a Quantitative Ultrasound Texture Analysis Model for Early Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: A Prospective Serial Imaging Study.

Cancers·2025

See all related articles